{"id":"sitaxsentan","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01244620","NCT01251835","NCT00995566","NCT00811018","NCT00303498","NCT00744211","NCT01100736","NCT01281371","NCT01050491","NCT01210443","NCT01251848","NCT00796666","NCT00080457","NCT01204853","NCT00034307","NCT01445873","NCT00810732","NCT00795639","NCT00981968","NCT00817037","NCT00838383","NCT00593905","NCT00796510","NCT01347216"],"aliases":["Sitaxsentan-Thelin","Thelin","Sitaxentan"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"brandName":"Sitaxsentan","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Endothelin B receptor, Endothelin-1 receptor, Endothelin-1 receptor","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Sitaxsentan","indications":{"approved":[{"name":"Pulmonary arterial hypertension","diseaseId":"pulmonary-arterial-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01244620","phase":"Phase 1","title":"A Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmacokinetic Interaction Between Sitaxsentan and Tadalafil and The Effect Of Sildenafil On Sitaxsentan P","status":"TERMINATED","sponsor":"Pfizer","isPivotal":false,"enrollment":16,"indication":"Pulmonary Arterial Hypertension","completionDate":"2010-12"},{"nctId":"NCT01251835","phase":"Phase 1","title":"A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects","status":"WITHDRAWN","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-01"},{"nctId":"NCT00995566","phase":"N/A","title":"Thelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin","status":"TERMINATED","sponsor":"Pfizer","isPivotal":false,"enrollment":54,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-02"},{"nctId":"NCT00811018","phase":"Phase 3","title":"A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":1192,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-07"},{"nctId":"NCT00303498","phase":"Phase 2","title":"A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":200,"indication":"Diastolic Heart Failure","completionDate":"2008-05-01"},{"nctId":"NCT00744211","phase":"NA","title":"Proteolytic Enzyme Induction Within the Human Myocardial Interstitium","status":"COMPLETED","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":29,"indication":"Heart Disease","completionDate":"2013-04"},{"nctId":"NCT01100736","phase":"EARLY/Phase 1","title":"Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man","status":"COMPLETED","sponsor":"University of Edinburgh","isPivotal":false,"enrollment":10,"indication":"Pulmonary Arterial Hypertension, Vasodilation","completionDate":"2010-01"},{"nctId":"NCT01281371","phase":"N/A","title":"Clinical Devolution of a Medication Change at Patients With Mono- or Combination Therapy With Sitaxentan to a Regime Without Sitaxentan.","status":"COMPLETED","sponsor":"Heidelberg University","isPivotal":false,"enrollment":9,"indication":"Hypertension, Pulmonary","completionDate":"2013-06"},{"nctId":"NCT01050491","phase":"Phase 2","title":"Effect of a Receptor Antagonist of Endothelin 1 (Sitaxsentan, Thelin) on Bronchial Remodeling in Severe Asthma With Fixed Bronchial Obstruction","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","isPivotal":false,"enrollment":17,"indication":"Effect of Sitaxsentan on Airway Remodeling in Severe Asthma","completionDate":"2010-12"},{"nctId":"NCT01210443","phase":"Phase 3","title":"A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":2,"indication":"Hypertension, Pulmonary","completionDate":"2010-12"},{"nctId":"NCT01251848","phase":"Phase 1","title":"A Phase 1, Open Label, Randomized, Multiple Dose Study To Assess The Two-Way Drug Interaction Between Sitaxsentan And Low Dose Ritonavir In Healthy Subjects","status":"WITHDRAWN","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-02"},{"nctId":"NCT00796666","phase":"Phase 3","title":"A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects Wit","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":131,"indication":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","completionDate":"2011-03"},{"nctId":"NCT00080457","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hyperten","status":"COMPLETED","sponsor":"Encysive Pharmaceuticals","isPivotal":true,"enrollment":240,"indication":"Pulmonary Hypertension","completionDate":"2005-01"},{"nctId":"NCT01204853","phase":"Phase 3","title":"A Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":2,"indication":"Hypertension, Pulmonary","completionDate":"2010-11"},{"nctId":"NCT00034307","phase":"Phase 2","title":"A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"ICOS-Texas Biotechnology","isPivotal":true,"enrollment":180,"indication":"Pulmonary Hypertension","completionDate":""},{"nctId":"NCT01445873","phase":"N/A","title":"NON-INTERVENTIONAL (NI) DRUG STUDY PROTOCOL: THREE-COUNTRY PILOT STUDY FOR RETROSPECTIVE CHART REVIEW OF EFFECTIVENESS OF THELIN® (SITAXSENTAN) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":36,"indication":"Pulmonary Arterial Hypertension","completionDate":"2011-03-28"},{"nctId":"NCT00810732","phase":"Phase 2","title":"THE EFFECTS OF SITAXSENTAN ONCE DAILY DOSING ON PROTEINURIA, 24-HOUR BLOOD PRESSURE, AND ARTERIAL STIFFNESS IN SUBJECTS WITH CHRONIC KIDNEY DISEASE","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":27,"indication":"Chronic Kidney Disease","completionDate":"2009-03-06"},{"nctId":"NCT00795639","phase":"Phase 3","title":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":183,"indication":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","completionDate":"2011-03"},{"nctId":"NCT00981968","phase":"Phase 1","title":"An Investigator- And Subjects- Blind Phase 1 Study To Investigate Pharmacokinetics, Safety And Tolerability Of Sitaxentan In Japanese Healthy Subjects Following Single And Multiple Doses And Western H","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":22,"indication":"Healthy","completionDate":"2009-11"},{"nctId":"NCT00817037","phase":"Phase 2","title":"The Effect of Sitaxsentan Once Daily Dosing on Proteinuria, 24-hour Systemic Blood Pressure, and Arterial Stiffness in Subjects With Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Edinburgh","isPivotal":false,"enrollment":27,"indication":"Chronic Kidney Disease, Proteinuria","completionDate":"2009-07-07"},{"nctId":"NCT00838383","phase":"Phase 2","title":"SELECTIVE ENDOTHELIN TYPE A RECEPTOR INHIBITION IN CARDIAC SURGERY SUBJECTS WITH PRE-EXISTING CARDIOVASCULAR RISK FACTORS: A DOSE CONFIRMATION STUDY","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":29,"indication":"Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement","completionDate":"2008-03-31"},{"nctId":"NCT00593905","phase":"N/A","title":"Pharmacogenomics in Pulmonary Arterial Hypertension: A Multi-Center International Study to Determine Whether in PAH Patients Clinical Associations Exist Between the Efficacy and Toxicity of Endothelin","status":"WITHDRAWN","sponsor":"West Penn Allegheny Health System","isPivotal":false,"enrollment":0,"indication":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","completionDate":"2012-07"},{"nctId":"NCT00796510","phase":"Phase 3","title":"A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pul","status":"TERMINATED","sponsor":"Pfizer","isPivotal":true,"enrollment":3,"indication":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","completionDate":"2011-01"},{"nctId":"NCT01347216","phase":"N/A","title":"Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension","status":"RECRUITING","sponsor":"Technische Universität Dresden","isPivotal":false,"enrollment":14000,"indication":"Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)","completionDate":"2026-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}